Search

Brian P Zambrowicz

from Sleepy Hollow, NY
Age ~62
Get Report
Also known as:
Brian Peter Zambrowicz, Brian Trus Zambrowicz, Brian Zambrowicz Ret, Brian Z, Brian N
Phone and address:
250 Kelbourne Ave, North Tarrytown, NY 10591
Related to:
Lyndon Shotwell, 37Belinda E Shotwell, 61Brenda C Zambrowicz, 62Sean M Duffy, 35Brandon S Shotwell, 41Rachel A Zambrowicz, 31Alfred ShotwellBrittney A Zambrowicz, 35
Connected to:
Gerald P Zambrowicz, 60Karolyn Zambrotta, 67Kevin A Zambrowicz, 55Lynne Zambrowski, 79Mark S Zambrovitz, 65Michael Zambrotta, 52Marek R Zambrzycki, 47Margaret Zambrzycki, 49April D Zambs, 63Arminda B Zambujo, 63

Brian Zambrowicz Phones & Addresses

  • 250 Kelbourne Ave, Tarrytown, NY 10591
  • Sleepy Hollow, NY
  • Ticonderoga, NY
  • Ossining, NY
  • White Plains, NY
  • Newbury Park, CA
  • Spring, TX
  • Seattle, WA

Work

Company: Regeneron pharmaceuticals, inc. Dec 2018 Position: Senior vice president functional genomics and chief of velocigene operations

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of Washington 1988 to 1993 Specialities: Biochemistry, Philosophy

Industries

Biotechnology

Resumes

Resumes

Brian Zambrowicz Photo 1

Senior Vice President Functional Genomics And Chief Of Velocigene Operations

View page
Location:
18 Firethorn Pl, Spring, TX 77382
Industry:
Biotechnology
Work:
Regeneron Pharmaceuticals, Inc.
Senior Vice President Functional Genomics and Chief of Velocigene Operations
Lexicon Pharmaceuticals, Inc.
Executive Vice President and Chief Strategy Officer at Lexicon Pharmaceuticals
Education:
University of Washington 1988 - 1993
Doctorates, Doctor of Philosophy, Biochemistry, Philosophy University of Wisconsin - Madison 1980 - 1984
Bachelors, Biochemistry

Publications

Us Patents

Methods And Compositions For Targeted Genetic Modification Through Single-Step Multiple Targeting

View page
US Patent:
20220235381, Jul 28, 2022
Filed:
Apr 5, 2022
Appl. No.:
17/713696
Inventors:
- Tarrytown NY, US
Lynn Macdonald - Harrison NY, US
Brian Zambrowicz - Sleepy Hollow NY, US
Andrew J. Murphy - Croton-on-Hudson NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
C12N 15/90
A01K 67/027
Abstract:
Methods and compositions are provided for making one or more targeted genetic modifications at a target genomic locus within a cell and for producing non-human animals comprising the modified genomic locus. The methods employ two or more large targeting vectors which are capable of recombining with each other and with the target genomic locus in a single genomic targeting step. The methods may also be employed in combination with a nuclease agent. Methods and compositions are also provided for enhancing homologous recombination at a target genomic locus in a cell. The methods employ two or more nucleic acids comprising one or more overlapping sequences. The methods may be employed in combination with a nuclease agent or without a nuclease agent.

Human Chromosome 9 Open Reading Frame 72 (C9Orf72) Irna Agent Compositions And Methods Of Use Thereof

View page
US Patent:
20230114649, Apr 13, 2023
Filed:
Jun 9, 2022
Appl. No.:
17/836020
Inventors:
- Cambridge MA, US
- Tarrytown NY, US
Kirk Brown - Swampscott MA, US
Tracy Zimmermann - Winchester MA, US
James D. McIninch - Burlington MA, US
David Frendewey - Tarrytown NY, US
Eric Chiao - Tarrytown NY, US
Anthony Gagliardi - Tarrytown NY, US
Gustavo Droguett - Tarrytown NY, US
Brittany Dubose - Tarrytown NY, US
Brian Zambrowicz - Tarrytown NY, US
International Classification:
C12N 15/113
A61P 25/28
Abstract:
The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a human chromosome 9 open reading frame 72 (C9orf72) gene, as well as methods of inhibiting expression of a C9orf72 gene and methods of treating subjects having a C9orf72-associated disease or disorder, e.g., C9orf72 amyotrophic lateral sclerosis/frontotemporal dementia or Huntington-Like Syndrome Due To C9orf72 Expansions, using such dsRNAi agents and compositions.

Non-Human Animals Comprising A Humanized Ttr Locus Comprising A V30M Mutation And Methods Of Use

View page
US Patent:
20230102342, Mar 30, 2023
Filed:
Mar 23, 2021
Appl. No.:
17/759539
Inventors:
- Tarrytown NY, US
Jeffery Haines - New York NY, US
Charleen Hunt - Montvale NJ, US
Guochun Gong - Pleasantville NY, US
Brian Zambrowicz - Sleepy Hollow NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A01K 67/027
C07K 14/47
Abstract:
Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TTR locus comprising a V30M mutation and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TTR locus express a human TTR protein or a chimeric TTR protein, fragments of which are from human TTR. Methods are provided for using such non-human animals comprising a humanized TTR locus to assess in vivo efficacy of human-TTR-targeting reagents such as nuclease agents designed to target human TTR.

Non-Human Animals Comprising A Humanized Ttr Locus And Methods Of Use

View page
US Patent:
20230078551, Mar 16, 2023
Filed:
Nov 22, 2022
Appl. No.:
18/057960
Inventors:
- Tarrytown NY, US
Jeffery Haines - New York NY, US
Suzanne Hartford - Putnam Valley NY, US
David Frendewey - New York NY, US
Brian Zambrowicz - Sleepy Hollow NY, US
Andrew J. Murphy - Croton-on-Hudson NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A01K 67/027
C12N 15/86
A61K 48/00
C12N 15/113
C07K 14/47
Abstract:
Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TTR locus and methods of using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TTR locus express a human transthyretin protein or a chimeric transthyretin protein, fragments of which are from human transthyretin. Methods are provided for using such non-human animals comprising a humanized TTR locus to assess in vivo efficacy of human-TTR-targeting reagents such as nuclease agents designed to target human TTR. Methods are also provided for making such non-human animals comprising a humanized TTR locus.

Crispr And Aav Strategies For X-Linked Juvenile Retinoschisis Therapy

View page
US Patent:
20230001019, Jan 5, 2023
Filed:
Nov 7, 2020
Appl. No.:
17/774284
Inventors:
- Tarrytown NY, US
Yang Liu - Valhalla NY, US
Guochun Gong - Pleasantville NY, US
Carmelo Romano - Tarrytown NY, US
Brian Zambrowicz - Sleepy Hollow NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A61K 48/00
C07K 14/705
C12N 15/86
C12N 15/90
C12N 9/22
C12N 15/11
A61P 27/02
Abstract:
Nucleic acid constructs and compositions that allow insertion and/or expression of a retinoschisin coding sequence are provided. Nuclease agents targeting RS1 loci are provided. Compositions and methods of using such constructs for integration into a target genomic locus and/or expression in a cell are also provided. Methods of treating X-linked juvenile retinoschisis using the nucleic acid constructs and compositions are also provided.

Cas-Ready Mouse Embryonic Stem Cells And Mice And Uses Thereof

View page
US Patent:
20210392862, Dec 23, 2021
Filed:
Aug 24, 2021
Appl. No.:
17/410437
Inventors:
- Tarrytown NY, US
Charleen Hunt - Montvale NJ, US
Daisuke Kajimura - Sleepy Hollow NY, US
Suzanne Hartford - Putnam Valley NY, US
Brian Zambrowicz - Sleepy Hollow NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A01K 67/027
Abstract:
Methods and compositions are provided herein for assessing CRISPR/Cas-mediated non-homologous end joining (NHEJ) activity and/or CRISPR/Cas-induced recombination of a target genomic locus with an exogenous donor nucleic acid in vivo and ex vivo. The methods and compositions employ cells and non-human animals comprising a Cas expression cassette such as a genomically integrated Cas expression cassette so that the Cas protein can be constitutively available or available in a tissue-specific or temporal-specific manner. Methods and compositions are also provided for making and using these non-human animals, including use of these non-human animals to assess CRISPR/Cas activity in vivo via adeno-associated virus (AAV)-mediated delivery of guide RNAs to the non-human animals.

Methods And Compositions For Assessing Crispr/Cas-Mediated Disruption Or Excision And Crispr/Cas-Induced Recombination With An Exogenous Donor Nucleic Acid In Vivo

View page
US Patent:
20210261985, Aug 26, 2021
Filed:
Apr 30, 2021
Appl. No.:
17/245405
Inventors:
- Tarrytown NY, US
Charleen Hunt - Montvale NJ, US
Susannah Brydges - Scarsdale NY, US
Suzanne Hartford - Putnam Valley NY, US
David Frendewey - New York NY, US
Brian Zambrowicz - Sleepy Hollow NY, US
Andrew J. Murphy - Croton-on-Hudson NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
C12N 15/90
C12N 15/861
C12N 15/877
A01K 67/027
C12N 9/38
Abstract:
Methods and compositions are provided for assessing CRISPR/Cas-mediated non-homologous end joining (NHEJ) activity and/or CRISPR/Cas-induced recombination of a target genomic locus with an exogenous donor nucleic acid in vivo or ex vivo. The methods and compositions employ non-human animals comprising a CRISPR reporter such as a genomically integrated CRISPR reporter for detecting and measuring targeted excision of a sequence between two CRISPR/Cas nuclease cleavage sites or disruption of a sequence near a CRISPR/Cas nuclease cleavage site and/or measuring CRISPR/Cas-induced recombination of the CRISPR reporter with an exogenous donor nucleic acid to convert the coding sequence for a first reporter protein to the coding sequence for a different second reporter protein. Methods and compositions are also provided for making and using these non-human animals.

Transcription Modulation In Animals Using Crispr/Cas Systems Delivered By Lipid Nanoparticles

View page
US Patent:
20210079394, Mar 18, 2021
Filed:
Sep 11, 2020
Appl. No.:
17/018680
Inventors:
- Tarrytown NY, US
Suzanne Hartford - Putnam Valley NY, US
Guochun Gong - Pleasantville NY, US
Brian Zambrowicz - Sleepy Hollow NY, US
International Classification:
C12N 15/113
C12N 9/22
A61K 9/00
A61K 47/69
Abstract:
Lipid nanoparticles comprising CRISPR/Cas synergistic activation mediator system components together in the same lipid nanoparticle and methods of using such lipid nanoparticles to increase expression of target genes in vivo and ex vivo and to assess CRISPR/Cas synergistic activation mediator systems for the ability to increase expression of target genes in vivo and ex vivo are provided.
Control profile
Brian P Zambrowicz from Sleepy Hollow, NY, age ~62 Get Report